Shirley R.  Kuhlmann net worth and biography

Shirley Kuhlmann Biography and Net Worth

Shirley R. Kuhlmann serves as Executive Vice President, General Counsel, Secretary of the Company. Ms. Kuhlmann has served as our Executive Vice President and General Counsel since March 2018. Prior to joining us, Ms. Kuhlmann was a corporate and securities attorney at Pepper Hamilton LLP from September 2007 until March 2018. At Pepper Hamilton, where she was made a partner effective January 2017, Ms. Kuhlmann advised private and public companies on a range of commercial and transactional matters, including financings, corporate governance and disclosure matters, and mergers and acquisitions and other business combination transactions. Ms. Kuhlmann holds a B.A. in Economics/Political Science from Columbia University in 2004 and a J.D. from Emory University School of Law in 2007.

What is Shirley R. Kuhlmann's net worth?

The estimated net worth of Shirley R. Kuhlmann is at least $4.15 million as of November 27th, 2023. Ms. Kuhlmann owns 119,518 shares of Collegium Pharmaceutical stock worth more than $4,152,055 as of April 23rd. This net worth evaluation does not reflect any other assets that Ms. Kuhlmann may own. Additionally, Ms. Kuhlmann receives a salary of $842,900.00 as EVP at Collegium Pharmaceutical. Learn More about Shirley R. Kuhlmann's net worth.

How old is Shirley R. Kuhlmann?

Ms. Kuhlmann is currently 40 years old. There are 5 older executives and no younger executives at Collegium Pharmaceutical. The oldest executive at Collegium Pharmaceutical is Dr. Thomas B. Smith FAAFP, M.D., Executive VP & Chief Medical Officer, who is 63 years old. Learn More on Shirley R. Kuhlmann's age.

What is Shirley R. Kuhlmann's salary?

As the EVP of Collegium Pharmaceutical, Inc., Ms. Kuhlmann earns $842,900.00 per year. There are 2 executives that earn more than Ms. Kuhlmann. The highest earning executive at Collegium Pharmaceutical is Mr. Joseph J. Ciaffoni, President, CEO & Director, who commands a salary of $1,690,000.00 per year. Learn More on Shirley R. Kuhlmann's salary.

How do I contact Shirley R. Kuhlmann?

The corporate mailing address for Ms. Kuhlmann and other Collegium Pharmaceutical executives is 100 Technology Center Drive, Stoughton MA, 02072. Collegium Pharmaceutical can also be reached via phone at (781) 713-3699 and via email at [email protected]. Learn More on Shirley R. Kuhlmann's contact information.

Has Shirley R. Kuhlmann been buying or selling shares of Collegium Pharmaceutical?

Shirley R. Kuhlmann has not been actively trading shares of Collegium Pharmaceutical during the last quarter. Most recently, Shirley R. Kuhlmann sold 25,600 shares of the business's stock in a transaction on Monday, November 27th. The shares were sold at an average price of $25.78, for a transaction totalling $659,968.00. Following the completion of the sale, the executive vice president now directly owns 119,518 shares of the company's stock, valued at $3,081,174.04. Learn More on Shirley R. Kuhlmann's trading history.

Who are Collegium Pharmaceutical's active insiders?

Collegium Pharmaceutical's insider roster includes Joseph Ciaffoni (Pres), Scott Dreyer (EVP), Michael Heffernan (Director), Shirley Kuhlmann (EVP), and Colleen Tupper (Exec. VP & CFO ). Learn More on Collegium Pharmaceutical's active insiders.

Are insiders buying or selling shares of Collegium Pharmaceutical?

During the last year, insiders at the specialty pharmaceutical company sold shares 7 times. They sold a total of 148,560 shares worth more than $3,755,011.80. The most recent insider tranaction occured on January, 16th when EVP Scott Dreyer sold 23,560 shares worth more than $760,516.80. Insiders at Collegium Pharmaceutical own 4.0% of the company. Learn More about insider trades at Collegium Pharmaceutical.

Information on this page was last updated on 1/16/2024.

Shirley R. Kuhlmann Insider Trading History at Collegium Pharmaceutical

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
11/27/2023Sell25,600$25.78$659,968.00119,518View SEC Filing Icon  
6/26/2023Sell17,984$21.72$390,612.48119,518View SEC Filing Icon  
2/13/2023Sell21,811$26.88$586,279.68137,502View SEC Filing Icon  
9/15/2022Sell38,589$18.07$697,303.23109,495View SEC Filing Icon  
8/11/2022Sell300$20.01$6,003.00148,084View SEC Filing Icon  
5/10/2021Sell7,000$22.77$159,390.0089,990View SEC Filing Icon  
1/20/2021Sell6,081$24.45$148,680.45102,891View SEC Filing Icon  
10/15/2020Sell7,060$20.82$146,989.2057,531View SEC Filing Icon  
See Full Table

Shirley R. Kuhlmann Buying and Selling Activity at Collegium Pharmaceutical

This chart shows Shirley R Kuhlmann's buying and selling at Collegium Pharmaceutical by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Collegium Pharmaceutical Company Overview

Collegium Pharmaceutical logo
Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain. The company was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. Collegium Pharmaceutical, Inc. was incorporated in 2002 and is headquartered in Stoughton, Massachusetts.
Read More

Today's Range

Now: $35.95
Low: $34.92
High: $36.13

50 Day Range

MA: $36.90
Low: $31.76
High: $40.91

2 Week Range

Now: $35.95
Low: $20.83
High: $40.95

Volume

290,204 shs

Average Volume

426,753 shs

Market Capitalization

$1.18 billion

P/E Ratio

30.47

Dividend Yield

N/A

Beta

1.03